A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

BACKGROUND: The survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results of a phase 1 study of talimogene laherparepvec...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Lucas, Teira, Pierre, Croop, James M., Gerber, Nicolas U., André, Nicolas, Aerts, Isabelle, Gros Subias, Luis, De Wilde, Bram, Bautista, Francisco, Turpin, Brian, Kunduri, Srinivasa, Hamidi, Ali, Lawrence, Tatiana, Streby, Keri A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244735/
https://www.ncbi.nlm.nih.gov/pubmed/37292376
http://dx.doi.org/10.3389/fped.2023.1183295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244735/
https://www.ncbi.nlm.nih.gov/pubmed/37292376
http://dx.doi.org/10.3389/fped.2023.1183295

Ejemplares similares